Skip to main content
Benaroya Research Institute

Main navigation

  • About BRI
    • Leadership
    • Faculty
    • Administrative Leaders
    • Together We Discover
    • Contact Us
  • Our Research
    • Centers of Discovery
      • Fundamental Immunology
      • Translational Immunology
      • Interventional Immunology
      • Systems Immunology
        • Bioinformatics at BRI
    • Labs
    • Biorepositories
      • Be a Part of BRI Research
    • Clinical Research
      • Allergies & Asthma Clinical Research
    • Core Labs
      • Cell And Tissue Analysis Group
      • Genomics Core
      • Human Immunophenotyping Core
      • Protein and Tetramer Core
        • Protein & Tetramer Core Ordering
    • Immune Tolerance Network
    • Scientific Publications
    • Scientific Meetings at BRI
      • Asthma Research Symposium
      • BRI Immunology Symposium: New Horizons in Immunity and Disease
      • Cross Autoimmunity Prevention Symposium
  • Collaborations with BRI
    • Opportunities for Collaboration
    • Technology Available for Licensing
  • News
    • Press Releases
  • Support our Research
    • Donate Now
    • BRI Events
      • BRI Open House
      • Immunology to Change Lives

Utility Menu

  • Immunology Learning Center
  • Autoimmune Life Blog
  • Careers
  • Clinical Research at VMMC
  • Donate
  • Search
    • Sep 2009

      Changes in autoreactive T cell avidity during type 1 diabetes development.

      Clin Immunol
      Standifer NE, Burwell EA, Gersuk VH, Greenbaum CJ, Nepom GT
    • Aug 2009

      Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

      Clin Immunol
      Herold KC, Gitelman S, Greenbaum CJ, Puck J, Hagopian WA, Gottlieb PA, Sayre PH, Bianchine PJ, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group.
    • Jul 2009

      The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis.

      J Clin Endocrinol Metab
      Ma X, Becker D, Arena VC, Vicini P, Greenbaum CJ
    • Dec 2008

      Type 1 Diabetes TrialNet--an international collaborative clinical trials network.

      Ann N Y Acad Sci
      Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, Type 1 Diabetes TrialNet Study Group.
    • Nov 2008

      The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.

      J Immunol
      Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum CJ, Buckner JH
    • Oct 2008

      Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.

      Diabetes Care
      Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, Type 1 Diabetes Trial Net Research Group., European C-Peptide Trial Study Group.
    • Aug 2008

      CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope.

      J Autoimmun
      Yang J, Danke N, Roti M, Huston L, Greenbaum CJ, Pihoker C , James EA, Kwok WW
    • Aug 2008

      Type 1 diabetes mellitus: primary, secondary, and tertiary prevention.

      Mt Sinai J Med
      Bollyky J, Sanda S, Greenbaum CJ
    • Jul 2008

      Health-related quality of life of children and adolescents with type 1 or type 2 diabetes mellitus: SEARCH for Diabetes in Youth Study.

      Arch Pediatr Adolesc Med
      Naughton MJ, Ruggiero AM, Lawrence JM, Imperatore G, Klingensmith GJ, Waitzfelder B, McKeown RE, Standiford DA, Liese AD, Loots B, SEARCH for Diabetes in Youth Study Group., Greenbaum CJ
    • Jun 2008

      Standardization of C-peptide measurements.

      Clin Chem
      Little RR, Rohlfing CL, Tennill AL, Madsen RW, Polonsky KS, Myers GL, Greenbaum CJ, Palmer JP, Rogatsky E, Stein DT
    • Apr 2008

      Use of oral glucose minimal model-derived index of insulin sensitivity in subjects with early type 1 diabetes mellitus.

      Metabolism
      Krudys KM, Greenbaum CJ, Pihoker C, Vicini P
    • Mar 2008

      A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.

      Diabetes Care
      Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS, Diabetes Prevention Trial-Type 1 Study Group.
    • Oct 2007

      Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes.

      J Immunol
      Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum CJ, Concannon P, Buckner JH
    • Sep 2007

      Role of insulin resistance in predicting progression to type 1 diabetes.

      Diabetes Care
      Xu P, Cuthbertson D, Greenbaum CJ, Palmer JP, Krischer JP, Diabetes Prevention Trial Type 1 Study Group.
    • Aug 2007

      Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out.

      J Clin Endocrinol Metab
      Bollyky J, Greenbaum CJ

Pagination

First page « First Previous page ‹ Previous … Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Next page Next › Last page Last »
Benaroya Research Institute

1201 Ninth Avenue
Seattle, WA 98101-2795
(206) 342-6500

facebook Bluesky instagram linkedin youtube threads
Resources
  • Support our Research
  • Subscribe to News
  • Careers
  • Contact Us
  • Research Conflicts of Interest
  • Research Security Program
  • Terms of Use
  • Research Requirements
If you would like to contact us regarding the accessibility of our website, please contact us at 206-342-6500 or email communications@benaroyaresearch.org.
© 2025 Benaroya Research Institute, a 501(c)(3) nonprofit organization
Close Close